The San Jose, California-based sacral neuromodulation (SNM) technology developer said Banerjee will lead activities in R&D and operations while working closely with all other functions. His appointment comes as the company completes a new FDA submission for its neuromodulation system. The company also has commercialization preparations underway for the system, which aims to treat overactive bladder (OAB).